Actively Recruiting
Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes
Led by Ain Shams University · Updated on 2025-04-30
20
Participants Needed
1
Research Sites
74 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Type 1 Diabetes is a chronic autoimmune disease. It results from autoimmune destruction of pancreatic Beta cells leading to absolute insulin insufficiency. The establishment of pluripotent like human stem cells derived from adipose tissue derived mesenchymal cell origin have introduced a new potential source for cell therapy in type 1 diabetic patients, especially in light of recent successes in producing glucose-sensitive insulin secreting cells and this will be the scope of this study. In the last decade, human clinical trials of introducing insulin producing stem cells from various origins were approved and conducted.
CONDITIONS
Official Title
Insulin Producing Stem Cell Transplantation Clinical Trial in Type 1 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Type 1 diabetes
You will not qualify if you...
- Patients with other autoimmune diseases
- Patients with micro or macro vascular complications
- Patients with other chronic diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Children Hospital Eldemerdash
Cairo, Egypt
Actively Recruiting
Research Team
R
Rasha S Elmetwally, MD
CONTACT
R
Rasha S Eladawy, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here